Syphilis Immunoassay Diagnostics

Global Syphilis Immunoassay Diagnostics Market to Reach US$445.1 Million by 2030

The global market for Syphilis Immunoassay Diagnostics estimated at US$356.6 Million in the year 2024, is expected to reach US$445.1 Million by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Analyzer, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$261.1 Million by the end of the analysis period. Growth in the Kit & Reagent segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$97.1 Million While China is Forecast to Grow at 6.8% CAGR

The Syphilis Immunoassay Diagnostics market in the U.S. is estimated at US$97.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$89.0 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Syphilis Immunoassay Diagnostics Market - Key Trends & Drivers Summarized

Why Are Immunoassay-Based Tests Becoming Central to Syphilis Diagnosis?

Syphilis immunoassay diagnostics have become a cornerstone in sexually transmitted infection (STI) screening due to their high specificity, scalability, and ability to detect both active and latent infections. These assays, which rely on antigen-antibody binding to detect Treponema pallidum, are employed across hospitals, sexual health clinics, and public health labs for routine and confirmatory testing. Their growing use is especially significant given the global resurgence of syphilis, including among high-risk populations and co-infected individuals with HIV.

Rapid point-of-care immunoassays are being adopted in decentralized healthcare settings, enabling faster treatment decisions, particularly in resource-limited regions. Automated immunoassay analyzers have become standard in centralized labs, offering high-throughput, multiplex testing alongside other STIs. Their integration into antenatal screening programs has also made them essential in preventing congenital syphilis. With increasing policy emphasis on early detection and treatment, immunoassay diagnostics now form the front line in syphilis control efforts worldwide.

How Is Technology Elevating Syphilis Immunoassay Diagnostic Accuracy and Reach?

The evolution of immunoassay platforms has significantly improved analytical performance. Chemiluminescent immunoassays (CLIA), enzyme-linked immunosorbent assays (ELISA), and fluorescence-based systems now offer superior sensitivity and specificity across different disease stages. Dual treponemal and non-treponemal antibody detection formats are being integrated to reduce false negatives and enable comprehensive serological profiling.

Miniaturization and microfluidics are enabling rapid immunoassays on handheld devices that deliver results within minutes without lab infrastructure. Multiplex immunoassays are being developed to test syphilis alongside HIV and hepatitis in a single cartridge. Additionally, AI-powered image recognition tools are being used to interpret lateral flow assays with greater consistency in low-skill settings. These technological advances are crucial for scaling up screening in vulnerable populations and in mobile healthcare units.

Where Is Immunoassay Adoption Increasing Most Rapidly for Syphilis Detection?

High-growth markets include sub-Saharan Africa, Southeast Asia, and Latin America—regions where syphilis prevalence is high and healthcare systems are undergoing diagnostic modernization. Public health initiatives are actively distributing rapid test kits in community clinics, mobile units, and maternal health programs to facilitate early diagnosis and reduce transmission.

Developed nations are expanding routine screening recommendations for high-risk groups, driving demand for lab-based immunoassays in sexual health clinics, blood banks, and correctional facilities. The private sector, including telehealth and at-home testing providers, is also incorporating immunoassays into direct-to-consumer STI kits. Together, these adoption channels are widening the reach and utility of syphilis immunoassay diagnostics across global health landscapes.

The Growth in the Syphilis Immunoassay Diagnostics Market Is Driven by Several Factors…

It is driven by the global rise in STI cases, advances in immunoassay sensitivity and portability, and increasing public health mandates for early and mass screening. The integration of automated, high-throughput platforms in clinical laboratories is streamlining large-scale screening efforts.

Point-of-care immunoassays with rapid turnaround are supporting diagnostics in remote or underserved regions, particularly within maternal and neonatal health programs. The growth of multiplex platforms and digitized assay interpretation tools is improving test accuracy and operational efficiency. Additionally, increased investment in infectious disease surveillance and international aid programs is expanding access to affordable, quality-assured diagnostic kits worldwide.

SCOPE OF STUDY:

The report analyzes the Syphilis Immunoassay Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Analyzer, Kit & Reagent); Technology (CLIA, ELISA); End-Use (Blood Bank End-Use, Diagnostic Lab End-Use, Hospital End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• AccuQuik (Jal Medical)
• Becton, Dickinson & Company (BD)
• bioMérieux SA
• Bio-Rad Laboratories
• Chembio Diagnostic Systems
• Danaher Corporation (Beckman Coulter)
• DiaSorin S.p.A.
• Fujirebio
• New Industries Biomedical Engineering (SNIBE)
• NOWDiagnostics (NOWDx)
• QuidelOrtho Corporation
• Roche Diagnostics (F. Hoffmann-La Roche)
• Sekisui Chemical Co., Ltd.
• Shenzhen New Industries Biomedical Engineering Co., Ltd.
• Siemens Healthineers AG
• Stanbio (Sekisui Specialty Diagnostics)
• Thermo Fisher Scientific, Inc.
• Trinity Biotech

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more